Effectiveness of colchicine among patients with COVID-19 infection: A randomized, open-labeled, clinical trial

Jalal et al., Indian Journal of Rheumatology, doi:10.4103/injr.injr_264_21, NCT04867226, May 2022

Colchicine for COVID-19

5th treatment shown to reduce risk in September 2020, now with p = 0.0000049 from 54 studies.
Lower risk for mortality, ICU, hospitalization, and recovery.

No treatment is 100% effective.
Protocols combine treatments.

6,700+ studies · 220+ treatments

c19early.org
Meta-analysis
Open label RCT of colchicine showing improved recovery with treatment. Only the abstract is currently available. Colchicine 0.5mg bid for 14 days.
This study is excluded in the after exclusion results of meta-analysis: minimal details provided.
Important missing comments or errors? Let us know.
hospitalization time, 24.1% lower, relative time 0.76, p = 0.009, treatment 36, control 44.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Jalal et al., 5 May 2022, Randomized Controlled Trial, Iraq, peer-reviewed, 3 authors, study period 8 May, 2021 - 18 June, 2021, trial NCT04867226 (history).
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org October 2026 Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Brazil France Italy Canada Pakistan Spain Vietnam Japan Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel Haiti North Macedonia Hong Kong Qatar Panama Serbia Iraq favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org October 2026 Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Brazil France Italy Canada Pakistan Spain Vietnam Japan Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Taiwan Fiji Zambia Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia Iraq favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
DOI record: { "DOI": "10.4103/injr.injr_264_21", "ISSN": [ "0973-3698" ], "URL": "http://dx.doi.org/10.4103/injr.injr_264_21", "alternative-id": [ "344591" ], "author": [ { "affiliation": [], "family": "Jalal", "given": "AryanMohamadfatih", "sequence": "first" }, { "affiliation": [], "family": "Aref", "given": "SheelanFaroz", "sequence": "additional" }, { "affiliation": [], "family": "Albustany", "given": "DashtyAbbas", "sequence": "additional" } ], "container-title": "Indian Journal of Rheumatology", "container-title-short": "Indian J Rheumatol", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2022, 5, 3 ] ], "date-time": "2022-05-03T03:21:24Z", "timestamp": 1651548084000 }, "deposited": { "date-parts": [ [ 2022, 5, 3 ] ], "date-time": "2022-05-03T03:22:20Z", "timestamp": 1651548140000 }, "indexed": { "date-parts": [ [ 2022, 5, 4 ] ], "date-time": "2022-05-04T13:15:53Z", "timestamp": 1651670153419 }, "is-referenced-by-count": 0, "issue": "0", "issued": { "date-parts": [ [ 2022 ] ] }, "journal-issue": { "issue": "0", "published-print": { "date-parts": [ [ 2022 ] ] } }, "language": "en", "member": "2581", "original-title": [], "page": "0", "prefix": "10.4103", "published": { "date-parts": [ [ 2022 ] ] }, "published-print": { "date-parts": [ [ 2022 ] ] }, "publisher": "Medknow", "reference-count": 20, "references-count": 20, "relation": {}, "resource": { "primary": { "URL": "http://www.indianjrheumatol.com/preprintarticle.asp?id=344591;type=0" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Rheumatology" ], "subtitle": [], "title": "Effectiveness of colchicine among patients with COVID-19 infection: A randomized, open-labeled, clinical trial", "type": "journal-article", "volume": "0" }
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0